As the Director of Preclinical Safety External Partnerships at Novartis, Kristin Henson plays a pivotal role in advancing the company’s commitment to innovative biomedical research. With a robust background in toxicology, gene therapy, and immunotoxicology, Kristin leverages her expertise to ensure the safety and efficacy...
As the Director of Preclinical Safety External Partnerships at Novartis, Kristin Henson plays a pivotal role in advancing the company’s commitment to innovative biomedical research. With a robust background in toxicology, gene therapy, and immunotoxicology, Kristin leverages her expertise to ensure the safety and efficacy of novel therapeutics throughout the drug development lifecycle. Her leadership in key projects focuses on establishing strategic collaborations that enhance preclinical safety assessments, particularly in the context of cutting-edge gene therapies and immunotherapies.
Kristin’s extensive experience in clinical pathology and regulatory submissions equips her with a unique perspective on navigating the complexities of drug discovery and development. She is adept at aligning scientific rigor with regulatory requirements, ensuring that all preclinical studies meet the highest standards of compliance and safety. Her proficiency in Good Manufacturing Practices (GMP) and clinical research further underscores her commitment to delivering high-quality therapeutics that can transform patient outcomes.
In her current role, Kristin is instrumental in fostering partnerships with external research organizations and academic institutions, facilitating knowledge exchange and resource sharing that drive innovation in the life sciences sector. Her work not only enhances Novartis's pipeline but also contributes to the broader field of immunology and vaccine development. As a thought leader in the industry, Kristin is dedicated to advancing scientific understanding and improving therapeutic strategies, making her a key asset to Novartis and the biomedical research community at large.
